LEGN vs. BNTX, TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, and MRNA
Should you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Legend Biotech vs. Its Competitors
Legend Biotech (NASDAQ:LEGN) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.
Legend Biotech presently has a consensus price target of $76.20, indicating a potential upside of 107.94%. BioNTech has a consensus price target of $137.86, indicating a potential upside of 28.76%. Given Legend Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Legend Biotech is more favorable than BioNTech.
In the previous week, BioNTech had 14 more articles in the media than Legend Biotech. MarketBeat recorded 18 mentions for BioNTech and 4 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.44 beat BioNTech's score of 0.31 indicating that Legend Biotech is being referred to more favorably in the media.
Legend Biotech has higher earnings, but lower revenue than BioNTech. Legend Biotech is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
Legend Biotech has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
BioNTech has a net margin of -27.37% compared to Legend Biotech's net margin of -29.95%. BioNTech's return on equity of -3.94% beat Legend Biotech's return on equity.
70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
BioNTech beats Legend Biotech on 10 of the 17 factors compared between the two stocks.
Get Legend Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Legend Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:LEGN) was last updated on 7/2/2025 by MarketBeat.com Staff
